ストックスクリーナーアプリを入手
0.86
4.44%
-0.04
前日終値:
$0.90
開ける：
$0.9999
24時間の取引高:
280.68K
Relative Volume:
1.03
時価総額：
$31.31M
収益：
-
当期純損益:
$-17.78M
株価収益率:
-1.5659
EPS:
-0.5492
ネットキャッシュフロー:
$-10.52M
1週間 パフォーマンス:
-21.82%
1か月 パフォーマンス:
-31.75%
6か月 パフォーマンス:
-70.34%
1年 パフォーマンス:
-92.46%
1日の値動き範囲:
$0.86
$0.9999
1週間の範囲:
$0.86
$1.12
52週間の値動き範囲:
$0.86
$13.59
Fibrobiologics Inc Stock (FBLG) Company Profile
FBLG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.86 | 31.31M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-24 | 開始されました | Maxim Group | Buy |
Fibrobiologics Inc (FBLG) 最新ニュース
Virtu Financial LLC Buys New Holdings in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges - Investing.com India
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Slashes Annual Losses by $5.3M as Key Clinical Trial Approaches - Stock Titan
Spotting Winners: TopBuild (NYSE:BLD) And Home Builders Stocks In Q4 - The Globe and Mail
FibroBiologics Announces 2025 Annual Meeting of Stockholders - GlobeNewswire
Biotech Pioneer FibroBiologics Reveals Massive 160+ Patent Portfolio at Upcoming Shareholder Meeting - Stock Titan
Applied Industrial (AIT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid FUBO and 1 Stock to Buy Instead - The Globe and Mail
Intuitive Machines Stock (LUNR) Lifts Off with 30% Surge Post Q4 Results - The Globe and Mail
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting - GlobeNewswire
FibroBiologics Announces Presentation on Innovative Fibroblast-Based Therapeutics at The German-Nordic Joint Extracellular Matrix Meeting - Nasdaq
FibroBiologics Reveals Groundbreaking Fibroblast Treatment Targeting 7 Major Diseases - Stock Titan
FBLG stock touches 52-week low at $0.98 amid sharp annual decline By Investing.com - Investing.com South Africa
FBLG stock touches 52-week low at $0.98 amid sharp annual decline - Investing.com Australia
Life Sciences Investor Forum Agenda Announced for March 13th - GlobeNewswire
FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an - GlobeNewswire Inc.
FibroBiologics files patent application for fibroblast-based therapeutics - TipRanks
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics - GlobeNewswire
Could FibroBiologics' New Mitochondrial Therapy Patent Transform Treatment for Chronic Diseases? - StockTitan
FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital - Defense World
FibroBiologics and Charles River Announce Completion and - GlobeNewswire
FibroBiologics and Charles River complete master cell bank for clinical trials - TipRanks
FibroBiologics Completes Master Cell Bank for CYWC628 in Collaboration with Charles River Laboratories - Nasdaq
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic - GlobeNewswire
Can This New Cell Therapy Breakthrough Finally Solve the Diabetic Foot Ulcer Crisis? - Stock Titan
FibroBiologics (FBLG) Expected to Announce Earnings on Thursday - Defense World
Fibrobiologics stock plunges to 52-week low of $1.04 By Investing.com - Investing.com Australia
Fibrobiologics stock plunges to 52-week low of $1.04 - Investing.com India
FBLG: Analyst Day Provides In-Depth Overview of Pipeline… - Zacks Small Cap Research
FibroBiologics' (FBLG) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
FibroBiologics’ (FBLG) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
Exploring Growth Opportunities In FibroBiologics Inc (NASDAQ: FBLG) - Stocks Register
D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Should This Give FibroBiologics Inc (NASDAQ: FBLG) Investors Sleepless Nights? - Stocks Register
FibroBiologics Inc (FBLG) stock analysis: A comprehensive overview - US Post News
FBLG (FibroBiologics Inc) may reap gains as insiders became active recently - Knox Daily
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView
FibroBiologics issues shares to fulfill commitment fee - MSN
FibroBiologics issues shares to fulfill commitment fee By Investing.com - Investing.com Australia
FibroBiologics Inc (FBLG) Stock: Navigating a Year of Volatility - The InvestChronicle
FibroBiologics Inc (NASDAQ: FBLG) Has Decreased By -81.41 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel
Should You Invest in FibroBiologics Inc (FBLG) Now? - The News Heater
FibroBiologics, Inc. to Host Analyst Day on Fibroblast-Based Therapeutics in New York on February 12, 2025 - Nasdaq
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates - GlobeNewswire
Exclusive Analyst Day: FibroBiologics to Unveil Future of Fibroblast Therapeutics - StockTitan
FibroBiologics And 2 Other US Penny Stocks To Watch - Simply Wall St
BlackRock, Inc. Increases Stake in FibroBiologics Inc - GuruFocus
Fibrobiologics Inc (FBLG) 財務データ
収益
当期純利益
現金流量
EPS
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):